Literature DB >> 32796235

Do damaging variants of SLC6A9, the gene for the glycine transporter 1 (GlyT-1), protect against schizophrenia?

David Curtis1,2.   

Abstract

The aim of the investigation was to test whether genetic variants predicted to impair the functionality of SLC6A9, which codes for the GlyT-1 glycine transporter, are protective against schizophrenia. In an exome sequenced sample of 4225 schizophrenia cases and 5834 controls, variants occurring in SLC6A9 were annotated and weights were assigned using GENEVARASSOC. Genotype counts were compared using SCOREASSOC. Variants predicted to be deleterious by SIFT and damaging by PolyPhen were examined. Genotypes at 1:44466494-G/A seemed likely to be erroneous. If these were ignored then there were 15 damaging variants in controls and five in cases. The results are consistent with the hypothesis that variants which damage SLC6A9 are protective against schizophrenia but a larger sample would be required to confirm this.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32796235      PMCID: PMC7882767          DOI: 10.1097/YPG.0000000000000260

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.574


  26 in total

1.  A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.

Authors:  Hsien-Yuan Lane; Ching-Hua Lin; Yu-Jhen Huang; Chun-Hui Liao; Yue-Cune Chang; Guochuan E Tsai
Journal:  Int J Neuropsychopharmacol       Date:  2009-11-04       Impact factor: 5.176

2.  Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine.

Authors:  Danielle L Taylor; Arun K Tiwari; Jeffrey A Lieberman; Steven G Potkin; Herbert Y Meltzer; Joanne Knight; Gary Remington; Daniel J Müller; James L Kennedy
Journal:  Mol Neuropsychiatry       Date:  2016-10-12

3.  Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Authors:  Hsien-Yuan Lane; Yue-Cune Chang; Yi-Ching Liu; Chih-Chiang Chiu; Guochuan E Tsai
Journal:  Arch Gen Psychiatry       Date:  2005-11

4.  Loss of Glycine Transporter 1 Causes a Subtype of Glycine Encephalopathy with Arthrogryposis and Mildly Elevated Cerebrospinal Fluid Glycine.

Authors:  Alina Kurolap; Anja Armbruster; Tova Hershkovitz; Katharina Hauf; Adi Mory; Tamar Paperna; Ewald Hannappel; Galit Tal; Yusif Nijem; Ella Sella; Muhammad Mahajnah; Anat Ilivitzki; Dov Hershkovitz; Nina Ekhilevitch; Hanna Mandel; Volker Eulenburg; Hagit N Baris
Journal:  Am J Hum Genet       Date:  2016-10-20       Impact factor: 11.025

Review 5.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

Authors:  Josep Dalmau; Eric Lancaster; Eugenia Martinez-Hernandez; Myrna R Rosenfeld; Rita Balice-Gordon
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

6.  Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.

Authors:  Hsien-Yuan Lane; Yi-Ching Liu; Chieh-Liang Huang; Yue-Cune Chang; Chun-Hui Liau; Cheng-Hwang Perng; Guochuan E Tsai
Journal:  Biol Psychiatry       Date:  2007-07-20       Impact factor: 13.382

7.  Analysis of protein-coding genetic variation in 60,706 humans.

Authors:  Monkol Lek; Konrad J Karczewski; Eric V Minikel; Kaitlin E Samocha; Eric Banks; Timothy Fennell; Anne H O'Donnell-Luria; James S Ware; Andrew J Hill; Beryl B Cummings; Taru Tukiainen; Daniel P Birnbaum; Jack A Kosmicki; Laramie E Duncan; Karol Estrada; Fengmei Zhao; James Zou; Emma Pierce-Hoffman; Joanne Berghout; David N Cooper; Nicole Deflaux; Mark DePristo; Ron Do; Jason Flannick; Menachem Fromer; Laura Gauthier; Jackie Goldstein; Namrata Gupta; Daniel Howrigan; Adam Kiezun; Mitja I Kurki; Ami Levy Moonshine; Pradeep Natarajan; Lorena Orozco; Gina M Peloso; Ryan Poplin; Manuel A Rivas; Valentin Ruano-Rubio; Samuel A Rose; Douglas M Ruderfer; Khalid Shakir; Peter D Stenson; Christine Stevens; Brett P Thomas; Grace Tiao; Maria T Tusie-Luna; Ben Weisburd; Hong-Hee Won; Dongmei Yu; David M Altshuler; Diego Ardissino; Michael Boehnke; John Danesh; Stacey Donnelly; Roberto Elosua; Jose C Florez; Stacey B Gabriel; Gad Getz; Stephen J Glatt; Christina M Hultman; Sekar Kathiresan; Markku Laakso; Steven McCarroll; Mark I McCarthy; Dermot McGovern; Ruth McPherson; Benjamin M Neale; Aarno Palotie; Shaun M Purcell; Danish Saleheen; Jeremiah M Scharf; Pamela Sklar; Patrick F Sullivan; Jaakko Tuomilehto; Ming T Tsuang; Hugh C Watkins; James G Wilson; Mark J Daly; Daniel G MacArthur
Journal:  Nature       Date:  2016-08-18       Impact factor: 49.962

8.  Weighted Burden Analysis of Exome-Sequenced Case-Control Sample Implicates Synaptic Genes in Schizophrenia Aetiology.

Authors:  David Curtis; Leda Coelewij; Shou-Hwa Liu; Jack Humphrey; Richard Mott
Journal:  Behav Genet       Date:  2018-03-21       Impact factor: 2.805

9.  A rapid method for combined analysis of common and rare variants at the level of a region, gene, or pathway.

Authors:  David Curtis
Journal:  Adv Appl Bioinform Chem       Date:  2012-07-24

10.  The Ensembl Variant Effect Predictor.

Authors:  William McLaren; Laurent Gil; Sarah E Hunt; Harpreet Singh Riat; Graham R S Ritchie; Anja Thormann; Paul Flicek; Fiona Cunningham
Journal:  Genome Biol       Date:  2016-06-06       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.